EPC-TM net represents a unique mix of people with different skills all dedicated towards a better understanding of the impact of different components of the tumour microenvironment on pancreatic cancer tumour progression. This team is drawn from different EU member states, cultures and backgrounds but all working together towards a common goal.

The coordinator of the EPC-TM net project is Prof. Dr. Thomas Gress from Philipps-Universität-Marburg (UNIMAR), Germany.

The consortium has been specifically designed to include all required levels of expertise:

  1. surgical and medical oncology groups conducting the largest clinical trials for pancreatic cancer in Europe,
  2. expert pancreatic pathologists,
  3. basic scientists focused on the study of carcinogenesis and tumour microenvironment interactions in the pancreas,
  4. molecular oncology groups that have developed genetically engineered mouse models faithfully recapitulating human pancreatic cancer, as well as
  5. pharmaceutical industry specialised on drug development.
Greifswald Madrid Verona Torino Milano Munich Fürstenfeldbruck Marburg Wuppertal Cambridge Liverpool Huddinge Stockholm
InstitutionShort nameCountry
Philipps-University of Marburg UNIMAR Germany
The University of Liverpool ULIV United Kingdom
Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III CNIO Spain
Universitá degli studi di Verona UNIVR Italy
Ernst-Moritz-Arndt-Universität Greifswald EMAU-G Germany
Karolinska Institutet KI Sweden
Axcentua Pharmaceuticals Limited Axcentua Sweden
Klinikum Rechts der Isar der Technischen Universität München TUM-MED Germany
Bayer Schering Pharma AG BSP Germany
Cancer Research UK CR-UK United Kingdom
Lab21 Limited Lab21 United Kingdom
Fondazione Centro San Raffaele del Monte Tabor HSR Italy
Universitá degli studi di Torino CeRMS-UniTO Italy
NatiMab Therapeutics SRL NatiMab Italy
concentris research management GmbH concentris Germany
Top